StockNews.com Downgrades Kura Oncology (NASDAQ:KURA) to Sell

Kura Oncology (NASDAQ:KURA) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Other equities research analysts have also recently issued reports about the stock. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Wednesday, November 13th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

Kura Oncology Stock Down 37.1 %

Shares of Kura Oncology stock opened at $10.00 on Wednesday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $9.06 and a 52-week high of $24.17. The company has a market capitalization of $777.68 million, a P/E ratio of -4.45 and a beta of 0.86. The company has a 50 day moving average of $18.28 and a 200 day moving average of $19.82.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC boosted its holdings in shares of Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after acquiring an additional 583,155 shares during the period. Vanguard Group Inc. grew its position in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC grew its position in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the last quarter. Finally, Artal Group S.A. boosted its stake in shares of Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after buying an additional 151,828 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.